ClinicalTrials.gg
RecruitingNCT05807932Updated Sep 16, 2026

Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML

A Phase 1/2 interventional study of Venetoclax and Amsacrine in Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia, sponsored by Heinrich-Heine University, Duesseldorf. Recruiting at 6 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Heinrich-Heine University, Duesseldorf · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
38
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies testing venetoclax in Myelodysplastic Syndromes — 17 open to participants now, 27 under way, 2 of them phase 3. venetoclax · Myelodysplastic Syndromes.

Planned enrollment
27th of 40
38 · median 58
Started
2023
with 4 others
Phase 1/2
10 of 40
2 open now
Primary completion
2029-04
later than 21 of 26 live
Registered
30th of 40
by date

Among the 40 studies testing venetoclax in Myelodysplastic Syndromes, this one is the 27th largest by planned enrollment, is one of 5 that started in 2023, is one of 10 in phase 1/2, reaches primary completion later than 21 of the 26 other live ones, and was the 30th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 318 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

17 of the 40 studies testing venetoclax in Myelodysplastic Syndromes are open now, in 6 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 259 Myelodysplastic Syndromes studies recruiting now, 166 (64%) set no upper age limit and 67 (26%) stop at 75 or younger; 55 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing venetoclax in Myelodysplastic Syndromes, or all of them as a file.
02

Study summary

This trial aims to find the MTD of Venetoclax when added to Fludarabin, Amsacrine and Ara-C + Treosulfan and to evaluate whether the addition of Venetoclax to sequential conditioning with FLAMSA + Treosulfan is safe for allogeneic blood stem cell transplantation in patients with high-risk MDS, CMML or sAML (FLAMSAClax)

03

Conditions studied

  • Myelodysplastic Syndromes
  • Secondary Acute Myeloid Leukemia
  • Chronic Myelomonocytic Leukemia

Keywords

  • MDS
  • sAML
  • CMML
  • allogeneic blood stem cell transplantation
  • Venetoclax
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must voluntarily sign and date an , approved by an independent ethics committee (IEC), prior to the initiation of any study-specific procedures
  • MDS, CMML or sAML according to WHO classification (revised version 2016) with a marrow blast count >5% and/or high-risk genetic features (e.g. bad risk karyotype according to the IPSS-R / ELN classification or presence of unfavorable somatic mutations (e.g. TP53, RUNX1, IDH1, IDH2, KMT2A, DEK-NUP214 or RAS pathway mutations including NRAS, KRAS, PTPN11, CBL, NF1, RIT1 or KIT), falling into the "high" or "very high" risk category of the IPSS-R or IPSS-M) any time between diagnosis and inclusion
  • Untreated except for oral Hydroxyurea or a maximum of 2 courses of treatment with Azacytidine or Decitabine alone or in combination with Venetoclax
  • Identification of a well matched (10 out of 10, A, B, C, DR, DQ) donor either related or unrelated
  • Age ≥18
  • HCT-CI ≤ 3 (except former treatment of a solid tumor)
  • performance status ≤ 2 at study entry
  • no active, uncontrolled infection at inclusion
  • able to adhere to the study visit schedule and other protocol requirements
  • Female of (FCBP) must:

    • Understand that based on embryo-foetal toxicity studies in animals venetoclax may harm the foetus when administered to pregnant woman
    • Agree to have a medically supervised pregnancy test at Screening and within 72 hours prior treatment start
    • Avoid becoming pregnant while receiving Venetoclax
    • Use effective during treatment with Venetoclax and for at least 1 months after the last dose,
    • Understand that is currently unknown whether venetoclax may reduce the effectiveness of hormonal contraceptives, and therefore women using hormonal contraceptives should add a barrier method
    • Notify her study doctor immediately if there is a risk of pregnancy
  • Males must:

    • agree to use condoms, even if the male subject has undergone a successful vasectomy, from Study Day 1 through at least 30 days after the last dose of study drug.
    • Agree to notify the investigator immediately, if pregnancy or a positive pregnancy test occurs in his partner during study participation

Exclusion criteria

Exclusion Criteria:

  • sAML with known FLT3 mutation (ITD or TKD)
  • Marrow blast count >30% at the time of screening
  • Peripheral white blood count >20,000 per microliter despite treatment with Hydroxyurea
  • previous cytotoxic therapy exceeding oral Hydroxyurea or >2 courses of treatment with Azacytidine, Decitabine or low dose Ara-C alone or in combination with Venetoclax
  • previous blood stem cell transplantation
  • symptomatic CNS-involvement with MDS; CMML or sAML
  • any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the form
  • pregnant or lactating females
  • Refusal to use safe methods during the study period
  • Cardiac history of CHF (> 2) requiring treatment or \< 40% or chronic stable angina
  • (FEV1) \<50% of expected corrected for and/or volume
  • Diffusing capacity of the lungs for carbon monoxide (DLCO) \<50% of expected corrected for hemoglobin and/or volume
  • any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study:

    • Impaired renal function ( \< 45 ml/min)
    • Impaired hepatic function, as follows (AST) ≥3 x or Alanine aminotransferase (ALT) ≥3 x ULN or Total ≥1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin) or Alkaline Phosphatase ≥3 x ULN
  • known to Venetoclax, Fludarabine, Amsacrine, Ara-C or Treosulfan
  • concurrent use of other anti-cancer agents or treatments except Hydroxyurea and a maximum of 2 courses of Azacytidine or Decitabine
  • positive for or replicating infectious hepatitis, type A, B, C or E
  • prior history of other than MDS, CMML, sAML (except basal cell or squamous cell carcinoma or carcinoma in situ of the cervix or breast) unless the subject has been free of disease for ≥ 2 years
  • participation in another study with ongoing use of unlicensed product from 28 days or \<5 half-lifes of the investigational product before study enrollment
  • No planned or executed/given treatment with any of the following within 7 days prior to the first dose of study drug (or ramp-up prophase):

    • therapy for anti-neoplastic intent
    • moderate or strong cytochrome P450 3A () inhibitors
    • moderate or strong CYP3A inducers
  • Refusal to avoid consumption of any of the following within 3 days prior to the first dose of study drug: grapefruit or grapefruit products, Seville oranges (including marmalade containing Seville oranges), star fruit.
  • Persons with any kind of dependency on the investigator or employed by the sponsor or investigator
  • Persons held in an institution by legal or official order
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (estimated)

Study arms

  • Experimental
    Venetoclax

    Venetoclax treatment will be started orally once a day with food, one day before FLAMSA conditioning therapy and stopped the day before high-dose Treosulfan. The total duration of treatment with Venetoclax will be 6 days (day -11 to -6 before stem cell infusion). Patients with active disease at transplant will receive a 3-day ramp-up prephase of Ara-C (100mg total dose infused in 1h) with daily increasing doses of Venetoclax to prevent TLS during conditioning. Total treatment duration with Venetoclax in patients with active disease at transplant will be 8 days (day -13 to -6 before stem cell infusion).

    Drug: Venetoclax · Drug: Amsacrine · Drug: Ara-C · Drug: Tacrolimus · Drug: Mycophenolate Mofetil

Interventions

  • Study treatment consists of the conditioning therapy including 6 or 8 days of Venetoclax treatment.

  • DrugAmsacrine

    Amsacrine is part of the conditioning therapy and is administered on day -10 to -7 before allogeneic blood stem cell transplantation

  • DrugCytarabineStudies of CytarabineCytarabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ara-C is part of the conditioning therapy and is administered on day -10 to -7 before allogeneic blood stem cell transplantation

  • Tacrolimus is used for prophylaxis of acute and chronic graft-versus-host-disease according to institutional standards.

  • DrugMycophenolic AcidStudies of Mycophenolic AcidMycophenolic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Mycophenolate Mofetil is used for prophylaxis of acute and chronic graft-versus-host-disease according to institutional standards.

06

What researchers measure

Primary outcomes

  1. The primary target variable is safety, defined as the maximal organ toxicity to each organ system according to CTC criteria as well as the number of AEs of grade III or greater within the first 30 days (± 3) after transplantation

    maximal organ toxicity to each organ system according to CTC criteria as well as the number of AEs of grade III or greater within the first 30 days (± 3) after transplantation

    Time frame: inclusion until day 30 (± 3) after transplantation

Secondary outcomes

  1. Safety, defined as the maximal organ toxicity to each organ system according to CTC criteria as well as the number of AEs of grade III or greater until day +100 (± 7) after transplantation

    maximal organ toxicity to each organ system according to CTC criteria as well as the number of AEs of grade III or greater until day +100 (± 7) after transplantation

    Time frame: inclusion until day +100 (± 7) after transplantation

  2. Graft failure at day +30 (± 3) after transplantation

    Number of patients with graft failure (no donor chimerism at day +30 (± 3) after transplantation)

    Time frame: transplantation until day +30 (± 3) after transplantation

  3. Incidence of aGvHD during the first 2 years after transplantation

    Incidence of aGvHD during the first 2 years after transplantation

    Time frame: transplantation until 2 years after transplantation

  4. Course of aGvHD during the first 2 years after transplantation

    Course of aGvHD during the first 2 years after transplantation (response/no response to steroids)

    Time frame: transplantation until 2 years after transplantation

  5. Severity of aGvHD during the first 2 years after transplantation

    Severity of aGvHD during the first 2 years after transplantation (according to Glucksberg criteria)

    Time frame: transplantation until 2 years after transplantation

  6. Incidence of cGvHD during the first 2 years after transplantation

    Incidence of cGvHD during the first 2 years after transplantation

    Time frame: transplantation until 2 years after transplantation

  7. Course of cGvHD during the first 2 years after transplantation

    Course of cGvHD during the first 2 years after transplantation (response/no response to steroids)

    Time frame: transplantation until 2 years after transplantation

  8. Severity of cGvHD during the first 2 years after transplantation

    Severity of cGvHD during the first 2 years after transplantation (according to NIH criteria)

    Time frame: transplantation until 2 years after transplantation

  9. Incidence, course and severity of VOD

    Incidence, course and severity of VOD (according to EBMT criteria)

    Time frame: transplantation until 2 years after transplantation

  10. Time to hematopoietic reconstitution

    Time (days from day 0) to hematopoietic reconstitution (ANC\>500/µl, PLT\>20000/µl and PLT\>50000/µl)

    Time frame: From date of transplantation (day 0) until the date of first documented hematopoietic reconstitution, assessed up to day 100

  11. Time to transfusion independence

    Time (days from day 0) to transfusion independence

    Time frame: From date of transplantation (day 0) until the date of first documented transfusion independence, assessed up to day 100

  12. Best disease response within the first 100 days (± 7) after transplantation

    Best disease response within the first 100 days (± 7) after transplantation (according to IWG-criteria for MDS and ELN-criteria for AML)

    Time frame: Transplantation to day 100 (± 7) after transplantation

  13. Disease response and donor chimerism at day +30 (± 3), +60 (± 7) and +100 (± 7) after transplantation

    Disease response and donor chimerism at day +30 (± 3), +60 (± 7) and +100 (± 7) after transplantation (according to IWG-criteria for MDS and ELN-criteria for AML)

    Time frame: Transplantation until days +30 (± 3), +60 (± 7) and +100 (± 7) after transplantation

  14. Time to complete donor chimerism in blood and marrow

    Time (days from day 0) to complete donor chimerism in blood and marrow

    Time frame: From date of transplantation (day 0) until the date of first documented donor chimerism in blood and marrow, assessed up to day 100

  15. Disappearance of molecular markers of disease

    Disappearance of individual molecular markers of disease (time in days from day 0)

    Time frame: From date of transplantation (day 0) until the date of first documented disappearance of individual molecular marker, assessed through study completion, an average of 2 years

  16. Event-free survival

    Event-free survival (death,relapse and disease progression will be recorded as event)

    Time frame: inclusion until 2 years after transplantation

  17. Cumulative incidence of relapse

    Cumulative incidence of relapse (disease progression and relapse will be recorded as event)

    Time frame: inclusion until 2 years after transplantation

  18. Overall survival

    Overall survival (OS, death will be recorded as event)

    Time frame: inclusion until 2 years after transplantation

07

Study locations

6 of 6 sites recruiting
  • Universitätsklinikum Aachen - Med. Klinik IV
    Aachen, North Rhine-Westphalia 52074, Germany
    Recruiting
    • Edgar Jost, Prof. Dr. · Contact
    • Edgar Jost, Prof. Dr. · Principal investigator
  • Universitätsklinikum Düsseldorf - Klinik für Hämatologie, Onkologie und Klinische Immunologie
    Düsseldorf, North Rhine-Westphalia 40225, Germany
    Recruiting
  • Universitätsklinikum Köln Klinik I für Innere Medizin
    Cologne, 50937, Germany
    Recruiting
    • Udo Holtick, PD Dr. · Contact
  • Universitätsklinikum Frankfurt Medizinische Klinik II
    Frankfurt, 60590, Germany
    Recruiting
    • Gesine Bug, PD Dr. · Contact
  • Universitätsklinikum Jena - Klinik für Innere Medizin II
    Jena, 07747, Germany
    Recruiting
    • Inken Hilgendorf, Prof. Dr. · Contact
    • Inken Hilgendorf, Prof. Dr. · Principal investigator
  • Klinikum rechts der Isar der TU München Klinik und Poliklinik für Innere Medizin III
    München, 81675, Germany
    Recruiting
    • Mareike Verbeek, Dr. · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Apr 2029, 70 months after the start.

Of 68 non-industry phase 1/2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 142. This study's planned 70 months is close to that.

Counting every sponsor, half of 109 studies reached it within 78 months; a quarter within 49 and three quarters within 110.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2023
First posted
Apr 11, 2023
StartActual
Jun 26, 2023
Primary completionEst.
Apr 30, 2029
CompletionEst.
Apr 30, 2029
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05807932
Collaborators
Koordinierungszentrum für Klinische Studien - Duesseldorf
Responsible party
Sponsor
First posted
Apr 11, 2023
Start date
Jun 26, 2023
Primary completion
Apr 30, 2029 (estimated)
Completion
Apr 30, 2029 (estimated)
Last update
Sep 16, 2026

Study contacts

Guido Kobbe, Prof. Dr.
Contact
kobbe@med.uni-duesseldorf.de
+492118116 ext. 826
Guido Kobbe, Prof. Dr.
principal investigator · Coordinating Investigator

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Venetoclax · Cytarabine

Start the discussion